OMICS International invites all the participants across the globe to attend the "Pharma Middle East Conference” slated on November 02-04, 2015 at Dubai, UAE.
OMICS Group International is a leading scientific event organizer, a pioneer and a union of open access publications, conferences, workshops, symposiums and exhibitions. OMICS Group International was established in the year 2007 and at present has pioneered the scientific world by publishing articles in about 400 Open Access Journals, conducting over 300 Scientific Meetings and numerous B2B Meetings. OMICS Group International is basking in the glory of success with the support of more than 1000 scientific associations, 30,000 editorial board members, and has gained 3.5 million followers in a span of 6 years to add to its credit. OMICS Group Conferences are scientific rostrums to unveil the novel developments and analyze the advantages and consequences by conglomerating au courant information in Science and Technology.Omics group Conferences has designed many UAE Pharma Conferences. OMICS Group also organizes many Middle East events 2015 which include medical and Pharma conferences in UAE where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions. OMICS International has started Pharma conferences in different continents all over the world like Middle East Pharma Conferences.
Pharma Middle East Conference which is an International Pharmacy Conference is a scientific platform to meet fellow key decision makers all-around the Academic Institutions, Healthcare Institutes, Pharmaceutical, Biotech, CROs supply chain, Logistics practitioners making the congress a perfect platform to share experience, foster collaborations through the research talks & presentations to put forward many thought provoking strategies. It's a perfect stage to brainstorm, discover new ideas, search for new skills and a platform to show your capabilities and discoveries to the world.Pharma Middle East will be one of the outstanding Middle East Pharma Conferences.
OMICS Group Conference Series provides a broad view of all the conferences along with past and up coming conferences all over the world.
The Pharma Industry is responsible for the development, production and marketing of medications. According to IMS Health Consulting, an international research company, in 2012 the size of the global pharmaceutical market reached $940 billion. In monetary terms it grew by 6%. In the future the sector is expected to grow at no less than 3% to 4% a year and if this happens the global pharmaceutical market is expected to reach $1.1 trillion by 2015 and will reach $1.2 trillion in 2016 and up to $1.5 trillion by 2020. The global demographic, epidemiological and economic changes are transforming the pharmaceutical market. The world population is growing rapidly and is projected to rise from 7 billion in 2011 to 7.7 billion in 2020 and 9.6 billion in 2050, hence an increase in the demand for pharmaceuticals. The global pharmaceuticals market is worth US$300 billion a year, a figure expected to rise to US$400 billion within three years. Economically, the Middle East (ME) is well positioned to be the one of next growth engine of global pharmaceutical business: several countries in the region enjoy robust economic growth and the highest cash reserves per capita in the world. The pharmaceutical Industry is consequently flourishing as the expanding middle class demands better care, and government healthcare spending continues to grow. The pharmaceutical market in the Middle East is likely to grow by between ten and 15 percent annually over the next three years, outstripping more mature markets, forecasts a report from URCH Publishing. The Middle East pharma markets are showing consistent growth over the last years in particular in the area of specialized medication. The market for pharmaceutical products is still expected to grow in many countries across the region.
The Middle East pharma market was valued at $14.8bn in 2008, registering a y-o-y sales growth of 12.6%, and is forecast to return at a CAGR of 8.1% between 2008 and 2014 to reach a total value of 23.5bn by the end of 2014. The general anti-infective market is expected to generate the highest sales of $3.9bn by the end of 2014, followed by alimentary canal & metabolic disorders at $3.7bn.
General anti-infectives, alimentary canal & metabolism and cardiovascular disorders remained as top selling therapeutic categories in the Middle East, while registering 2008 sales of $2.6bn, $2.3bn and $1.9bn respectively.
The leading brands in the Middle East pharmaceutical market had a predominance of respiratory and cardiovascular drugs. However, the top 10 brands constituted a very small fraction of the Middle East market, with other drugs making up 94.1% of the total market in 2008. GSK's asthma and COPD drug Seretide dominated the market with 2008 sales of $134m, a strong growth of 21% over 2007